GeneThera, Inc. and UTEK Corporation Announce Strategic Alliance Agreement for Technology Transfer.

Business Editors

WHEAT RIDGE, Colo. & PLANT CITY, Fla.--(BUSINESS WIRE)--Jan. 26, 2004

GeneThera Inc., a molecular biotechnology company (OTCBB:GTHA), and UTEK Corporation (AMEX:UTK), an innovative technology transfer company, announced jointly today the signing of a Strategic Alliance Agreement. The goal of the agreement is to have UTEK identify and engage suitable partners for GeneThera's technology in the United States and the United Kingdom.

According to Antonio Milici, M.D., Ph.D., CEO of GeneThera: "GeneThera recently announced that it has developed a new system for the collection of blood and the testing of live cattle for Mad Cow Disease and that it is seeking to work with both state and federal agencies in order to validate this new test. GeneThera is very pleased to retain UTEK Corporation to help identify strategic partners for GeneThera at this crucial stage in its technology introduction."

"UTEK looks forward to working with GeneThera to help bring their intellectual capital to the market place," commented Clifford M. Gross, Ph.D., Chief Executive Officer of UTEK Corporation.

About GeneThera, Inc.

GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, Colorado. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The Company's proprietary diagnostic solution is based on a genetic expression assay, GEA(TM), a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GEA is designed for a host of individual diseases, the current priority being Chronic Wasting Disease, a disease affecting elk and deer in North America; E.Coli 0157:H7 and Mad Cow Disease, affecting cattle worldwide. For more information on GeneThera, Inc., please visit their website at http://www.genethera.net.

About UTEK Corporation

UTEK(R) is an innovative technology transfer company dedicated to building bridges between university-developed technologies and commercial organizations. UTEK, along with its TechEx and UVentures technology exchanges and its PAX European subsidiary, identifies and transfers new technologies from universities and research centers to the marketplace. UTEK provides research-outsourcing services to commercial enterprises and technology-transfer services to research institutions. For more information about UTEK, please visit their website at http://www.utekcorp.com.

Forward Looking Statements

Certain matters discussed in this press release are "forward-looking statements." These forward-looking statements can generally be identified as such because the context of the statement will include words such as UTEK or GeneThera "believes," "anticipates" or words of similar import. Similarly, statements that describe UTEK's or GeneThera's future plans, including the commercial viability of the tests introduced by GeneThera, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of UTEK or GeneThera, as appropriate, and market valuations of their stock, which could cause actual results to differ materially from those currently anticipated. Although UTEK and GeneThera, as appropriate, believe the expectations reflected in any forward-looking statements are based on reasonable assumptions, they can give no assurance that their expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Forward-looking statements made herein are only made as of the date of this press release and neither UTEK nor GeneThera, as appropriate, undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

UTEK's operating results could fluctuate significantly due to a number of factors. These factors include the small number of transactions that are completed each quarter, the value of individual transactions, the timing of the recognition and the magnitude of unrealized gains and losses, UTEK's dependence on the performance of companies in its portfolio, the possibility that advances in technology could render the technologies it has transferred obsolete, the loss of technology licenses by companies in its portfolio, the degree to which it encounters competition in its markets, the volatility of the stock market and the volatility of the valuations of the companies it has invested in as it relates to its realized and unrealized gains and losses, the concentration of investments in a small number of companies, as well as other general economic conditions. As a result of these factors, current results may not be indicative of UTEK's future performance. For more information on UTEK and for a more complete discussion of the risks pertaining to an investment in UTEK, please refer to UTEK's filings with the Securities and Exchange Commission.